NR3C1 and neoplasm: NR3C1 is revealed to be associated with the failure of checkpoint blockade [50], and the loss of NR3C1 potentiates the response to checkpoint blockade, suggesting inhibiting NR3C1 is a potential strategy to improve anti-tumor immune responses in combination with other treatments.